Evidence map›Paper›PMID 40856496›Full record

ArticleMicrobiology spectrum2025

Improved detection of isoniazid-heteroresistant

Haoran Li, Nan Wang, Mengjie Yang, Yuanyuan Shang, Yilin Wang, Chianru Tan, Shufang Wen, Yong Guo, Yu Pang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haoran Li *Department of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Nan Wang *School of Biomedical Engineering, Tsinghua University, Beijing, People's Republic of China.
Mengjie Yang *Department of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0009-0007-4974-1693
Yuanyuan ShangDepartment of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Yilin WangDepartment of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Chianru TanSchool of Biomedical Engineering, Tsinghua University, Beijing, People's Republic of China.
Shufang WenDepartment of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Yong GuoSchool of Biomedical Engineering, Tsinghua University, Beijing, People's Republic of China.ORCID 0000-0003-3175-3008
Yu PangDepartment of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.ORCID 0000-0001-6803-9807

Funding

Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park Z221100007422056, Z221100007422064Beijing Nova Program 20220484169, 20230484295Natural Science Foundation of Beijing Municipality International Scientists Project 1S24095Science and Technology Program of Guangzhou 2023A03J0991The Science and Technology Plan Project of Tongzhou District, Beijing KJ2024CX028
6 · The paper itself

Abstract

Drug resistance in IMPORTANCE: Tuberculosis has emerged as a significant threat to global health, bringing numerous new cases and a large number of deaths annually. Isoniazid (INH), as a first-line treatment drug, plays a crucial role. However, the emergence of its drug resistance poses a tough challenge for tuberculosis control. Currently, the methods for detecting INH resistance and heteroresistance have limitations like the slow speed of traditional culture tests and the insufficient sensitivity of molecular methods. Therefore, improving the diagnostic efficacy of the detection results for INH resistance is crucial for the treatment of tuberculosis.

Indexed as

Antitubercular AgentsDrug Resistance, BacterialIsoniazidMycobacterium tuberculosisPolymerase Chain ReactionTuberculosis, Multidrug-ResistantChinaHumansMicrobial Sensitivity TestsMutationSensitivity and SpecificityTuberculosisAntitubercular AgentsIsoniaziddroplet digital PCRheteroresistanceisoniazidMycobacterium tuberculosis

Identifiers

PMID40856496
PMCPMC12502712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.